Trials / Completed
CompletedNCT01178827
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | trospium chloride | trospium chloride (60mg) once daily for 10 days |
| DRUG | oxybutynin IR | oxybutynin IR (5 mg) three times daily for 2 days |
| DRUG | oxybutynin IR placebo | oxybutynin IR placebo three times daily for 2 days |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2010-08-10
- Last updated
- 2016-02-26
- Results posted
- 2012-08-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01178827. Inclusion in this directory is not an endorsement.